Similarly, there was a trend toward a higher frequency of DAPK1 methylaton in patients with lymph node metastasis than without metastasis (OR = 5.17, 95% CI = 0.64-42.0) (Figure 3). This evidence concerns the gene DAPK1 and metastatic malignant neoplasm in the lymph nodes.